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Abstract
Background: Depression is a common psychiatric complication of diabetes, but little is known about the natural
course and the consequences of depressive symptoms in primary care patients with type 2 diabetes. While
depression has been related to poor glycemic control and increased risk for macrovascular disease, its association
with microvascular complications remains understudied. The predictive role of other psychological risk factors such
as Type D (distressed) personality and the mechanisms that possibly link depression and Type D personality with
poor vascular outcomes are also still unclear.
Methods/Design: This prospective cohort study will examine: (1) the course of depressive symptoms in primary
care patients with type 2 diabetes; (2) whether depressive symptoms and Type D personality are associated with
the development of microvascular and/or macrovascular complications and with the risk of all-cause or vascular
mortality; and (3) the behavioral and physiological mechanisms that may mediate these associations. The
DiaDDZoB Study is embedded within the larger DIAZOB Primary Care Diabetes study, which covers a
comprehensive cohort of type 2 diabetes patients treated by over 200 primary care physicians in South-East
Brabant, The Netherlands. These patients will be followed during their lifetime and are assessed annually for
demographic, clinical, lifestyle and psychosocial factors. Measurements include an interviewer-administered and
self-report questionnaire, regular care laboratory tests and physical examinations, and pharmacy medication
records. The DiaDDZoB Study uses data that have been collected during the original baseline assessment in 2005
(M0; N = 2,460) and the 2007 (M1; N = 2,225) and 2008 (M2; N = 2,032) follow-up assessments.
Discussion: The DiaDDZoB Study is expected to contribute to the current understanding of the course of
depression in primary care patients with type 2 diabetes and will also test whether depressed patients or those
with Type D personality are at increased risk for (further) development of micro- and cardiovascular disease. More
knowledge about the mechanisms behind this association is needed to guide new intervention studies.
Background
The number of people with diabetes mellitus is increas-
ing rapidly worldwide. Based on aging and other demo-
graphic changes, prevalence estimates of this chronic
metabolic disease are projected to rise from 171 million
in 2000 to 366 million in 2030 [1]. As the disease pro-
gresses, diabetes patients are often confronted with
long-term vascular complications. While premature car-
diovascular disease (including coronary artery disease,
stroke and peripheral arterial disease) accounts for con-
siderable morbidity and mortality, complications of
microvascular origin also contribute significantly to
adverse health outcomes [2]. To date, diabetes remains
a predominant cause of vision loss, renal failure and
lower extremity amputations in developed countries [3].
A large-scaled study among over 7,000 patients with
type 2 diabetes in eight European countries concluded
that approximately 72% of the participants had at least
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had both micro- and macrovascular complications [4].
Not surprisingly, the presence of these vascular condi-
tions has a substantial negative impact on both overall
healthcare expenditures [4] and patients’ quality of
life [5].
Depression is common in type 2 diabetes
Depression is another common and burdensome com-
plication of type 2 diabetes. A recent meta-analysis of
ten controlled studies showed that the prevalence of
depression was significantly higher in patients with type
2 diabetes compared with non-diabetic controls (18 vs.
10%, OR = 1.6, 95% CI 1.2-2.0) [6]. Even though depres-
sion is a common co-morbidity in diabetes, little longi-
tudinal research has been undertaken with respect to its
natural course in type 2 diabetes [7]. A meta-analysis of
seven prospective studies by Mezuk et al., all excluding
prevalent cases of depression at baseline, concluded that
the association between type 2 diabetes and the inci-
d e n c eo fd e p r e s s i o ni so n l ym o d e s t( R R=1 . 1 5 ,9 5 %C I
1.02 - 1.30) [8]. However, a negative depression screen-
ing score at study entry cannot rule out a history of
depression and therefore the conclusion by Mezuk et al.,
about the role of diabetes as a risk factor for “new” cases
of depression, might be premature [9]. Two meta-ana-
lyses showed that the reversed association, with depres-
sion as a risk factor for the onset of type 2 diabetes, is
stronger. Depressed adults have a 30-60% increased risk
of developing type 2 diabetes [8,10].
There is abundant evidence showing that depression
can be regarded as a chronic condition for many
patients, with periods of (partial) remission and relapse
in community [11] and primary care [12] samples.
Although the existing literature suggests that depression
is even more persistent in diabetes patients, these stu-
dies are hampered by relatively small numbers of type 2
diabetes patients [7,13], the inclusion of selected popula-
tions from specialised clinics [14] and the measurement
of depression in a selected sample of patients who have
participated in an antidepressant drug trial [13] or dia-
betes education programme [7,15]. A large study exam-
ining different aspects of the natural course (incidence,
remission, recurrence) of depression in a representative
sample of primary care patients with type 2 diabetes is
currently lacking.
Depression is associated with poor disease outcomes
Depression in diabetes was found to be associated with
poor glycemic control [16], a higher number of cardio-
vascular risk factors [17], micro- and macrovascular
complications [18], and an increased mortality risk
[19-22]. Meta-analyses of prospective studies suggest
that depression is associated with the onset or
progression of cardiovascular disease in primary care
and community samples [23] and post-myocardial
infarction patients [24]. An important limitation of the
current diabetes literature is that most studies on the
association between depression and vascular conditions
used cross-sectional data [18], hence precluding any
inferences about possible causal pathways. In recent
years, a limited number of prospective studies have been
published. While depression predicted the incidence of
vascular complications [19,25] and greater all-cause
mortality [19-22], its effect on mortality due to vascular
causes still is unclear [20,2 6 ] .S of a r ,t h ee m p h a s i si n
these studies has been on macrovascular outcomes, in
particular coronary heart disease. Only two large longi-
tudinal studies have considered the association between
depression and the incidence of microvascular condi-
tions. One of these was conducted in a sample of elderly
Mexican-Americans and used self-report to ascertain
the presence of complications [19], while the other
only examined advanced complications, including
end-stage renal disease, low vision or blindness, and
amputations [27].
Type D personality and cardiovascular disease
Most research on the psychological aspects of diabetes
has focused on depression, leaving the role of other
dimensions of emotional distress, such as anxiety and
more stable emotional traits, as understudied areas. An
emerging risk factor in the cardiovascular research
domain is “Type D (distressed) personality”,w h i c hi s
d e f i n e db yt h et w os t a b l ep e r s o n a l i t yt r a i t s“negative
affectivity” and “social inhibition” [28]. Individuals with
this personality type tend to experience negative emo-
tions across time and situations, but are inclined to inhi-
bit the expression of emotions and behaviors in order to
avoid disapproval or rejection [28,29]. Type D personal-
ity is relatively common, with prevalence estimates ran-
ging from 21% in the general population to 28% in
coronary heart disease patients and 53% in hypertensives
[28]. Accumulating evidence suggests that having a Type
D personality is associated with a 2 to 5-fold increased
risk of adverse prognosis, impaired quality of life and
emotional distress across cardiovascular patient groups,
independent of standard biomedical risk factors [29,30].
No studies to date have been undertaken to examine
the impact of Type D personality on disease-related out-
comes in patients with type 2 diabetes, although vascu-
lar disease is relatively common in this group.
Mechanisms that could link depression and Type D with
poor outcomes
Several plausible mechanisms have been hypothesized to
mediate the association between emotional distress
(depression, Type D) and poor vascular outcomes.
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smoking, alcohol consumption and physical inactivity,
and biomedical factors (e.g. underlying cardiac disease
severity, an unfavorable cardiovascular risk profile/the
“metabolic syndrome”, immune processes) [31-33]. In
the Heart and Soul Study, a cohort of more than 1,000
outpatients with stable coronary heart disease, the asso-
ciation between depressive symptoms and adverse cardi-
ovascular events was largely explained by behavioral
factors, in particular physical inactivity (32% change in
effect size) [33]. The extent to which these mechanisms
account for the increased risk of vascular complications
in distressed diabetes patients, should this association
exist, is still unclear.
Innovative aspects of the DiaDDZoB Study
To summarize: (1) While there are numerous studies
that aimed to determine the prevalence of depression in
type 2 diabetes patients, little is known about the nat-
ural course of depression in diabetes (incidence, recur-
rence, remission). (2) The majority of studies examining
the association between emotional distress and vascular
disease had a cross-sectional design, focused on depres-
sion and had macrovascular disease as outcome. The
role of other aspects of emotional distress and the asso-
ciation with common microvascular complications is
therefore still unclear. (3) It is unknown which beha-
vioral and/or biomedical mechanisms may account for
the hypothesized associations between emotional dis-
tress and vascular conditions. The DiaDDZoB Study
(Diabetes, Depression, Type D Personality Zuidoost-
Brabant) will examine the abovementioned issues in a
cohort of primary care patients with type 2 diabetes.
Methods/Design
Aims and hypotheses
The DiaDDZoB Study was designed as a prospective
cohort study and aims to address the following main
research questions:
1. What is the natural course (prevalence, incidence,
recurrence, remission) of depressive symptoms in a sam-
ple of primary care patients with type 2 diabetes?
2. Do patients with type 2 diabetes and co-morbid
emotional distress (as evidenced by an increased level of
depressive symptoms and/or Type D personality) have
an increased risk for the onset/progression of micro-
and macrovascular complications?
3. Do these types of emotional distress also increase
the risk of all-cause or vascular mortality?
4. When a significant relation is found in (2) or (3):
which factors mediate the association between emo-
tional distress and diabetes outcomes?
Based on the current literature, we hypothesize the
following: Approximately one fifth of our sample will
have an increased level of depressive symptoms at each
separate measurement occasion (prevalence). In the
group of patients without a self-reported history of
depression, incident depression will be low (< 5%). In
the patients with a history of depression, recurrence
rates will be relatively high (at least 25%). Significant
risk factors for depression most likely will be: (1) psy-
chosocial factors such as stressful life events and loneli-
n e s sa n d( 2 )t h ep r e s e n c e( o n s e to rp r o g r e s s i o n )o f
vascular complications. We also hypothesize that
patients with co-morbid distress (either depressive
symptoms or Type D) will be at increased risk for the
development of micro- and macrovascular conditions
and both all-cause and vascular mortality; these associa-
tions are (partly) explained by behavioral (smoking
behavior, alcohol consumption, physical inactivity) and
biomedical (cardiovascular disease history, characteris-
tics of the metabolic syndrome) mechanisms.
Study design
From 2005 onwards, data for the DiaDDZoB Study have
been collected within the framework of the DIAZOB
(Diabetes care Zuidoost-Brabant) project, a large-scale
diabetes management programme for primary care
patients with type 2 diabetes. To evaluate the implemen-
tation of this standard diabetes care programme in daily
practice, an observational cohort study (the DIAZOB
Primary Care Diabetes study) was designed, including
annual assessments of a broad range of demographic,
medical, lifestyle and psychosocial factors [34,35]. Fol-
low-up surveys of the total DIAZOB population (N ≈
12,000) are planned for the upcoming years. The Dia-
DDZoB Study builds upon data from three completed
measurement occasions. The original baseline measure-
ment (M0) took place in the second half of 2005. Fol-
low-up assessments were realized in 2007 (M1)a n d
2008 (M2).
Subjects
The ongoing assessment of the DIAZOB-cohort is
conducted in collaboration with over 200 general practi-
tioners who are currently allied to PoZoB (Praktijkon-
dersteuning Zuidoost Brabant), a large managed care
organisation responsible for the implementation of the
DIAZOB standard care programme. The practices are
located in the South-Eastern area of the Netherlands,
mainly in the region south of the city of Eindhoven. The
patient population is residing in rural and suburban
areas. To be included in the DIAZOB Primary Care Dia-
betes study, the patient had to be formally diagnosed
with type 2 diabetes according to the guidelines of the
Dutch College of General Practitioners (as evidenced by
either a fasting glucose concentration of > 6.9 mmol/l in
venous plasma or > 6.0 mmol/l in capillary blood on
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mmol/l in the presence of the classic hyperglycemia
symptoms [36]. These criteria are comparable to the
recommendations of the American Diabetes Association
[37]. Other inclusion criteria were: the patient was
receiving treatment for diabetes in the DIAZOB diabetes
care programme, had the primary care practice nurse as
his/her main health care provider for diabetes issues,
was at least 18 years old (with no upper age limit) and
had sufficient mastery of the Dutch language. Patients
were excluded if they had a treatment or condition
other than type 2 diabetes as the primary cause of the
hyperglycemia and/or were physically/mentally incapable
of completing a questionnaire (e.g. co-morbid dementia,
terminal cancer), as judged by the primary care practice
nurse.
Recruitment of patients
From 2005 onward, patients were invited by their pri-
mary care practice nurse to participate in the DIAZOB
standard care project. In the period of April (pilot) and
June - December 2005, the DIAZOB patients were
informed of the evaluation study and received a detailed
description of its practical and scientific aim. Patients
who were willing to participate were asked to sign an
informed consent form. Consent was sought for (a) using
the anonymised data (questionnaire and medical infor-
mation) for reports and scientific publications; requesting
information from the patient’s (b) pharmacist and (c)
specialist; and (d) informing the general practitioner or
primary care practice nurse of study results, if necessary.
Participant drop-out
In the beginning of 2005, the total number of type 2 dia-
betes patients in the area covered by the participating gen-
eral practitioners at that time was estimated at 3,000 to
3,500. During the baseline inclusion period, 3,017 patients
were considered for participation in the study. A detailed
overview of the study’s participation and drop-out rate can
be found in Figure 1. Reasons for baseline non-response
could be grouped into “patient characteristics” (e.g. not
meeting inclusion criteria/screening positive on exclusion
criteria, refusing to participate, not showing up at the
baseline interview) and “practice nurse characteristics”
(lack of time, omitting to invite newly diagnosed or insu-
lin-using patients). Of the resulting 2,460 patients, 2,448
(99.5%) attended the interview and 1,850 (75.2%) returned
the self-report questionnaire that had to be filled in at
home. For the M1 and M2 assessments, 2,225 and 2,032
patients were available, respectively.
Measures used in the DiaDDZoB Study
The DIAZOB Primary Care Diabetes study measure-
ments include an interviewer-administered and
self-report questionnaire, results from regular care
laboratory tests and physical examinations, and phar-
macy medication records. An overview of the variables
that were used for the DiaDDZoB Study can be found
in Table 1.
Data acquired during an interview with the primary care
practice nurse
The interview-administered questionnaire was filled out
by the practice nurse along with the patient during reg-
ular diabetes check-up and included questions about
demographic factors, clinical parameters, hyperglycemia
treatment and health behaviors.
Demographics Information was gathered about age,
gender and ethnicity.
Clinical parameters At baseline, the primary care prac-
tice nurse recorded the number of months/years since
diabetes diagnosis and took a basic medical history,
including self-reported history of depression. Self-
reported medical diagnoses were verified through inspec-
tion of the medical record. At follow-up, onset and/or
progression of vascular complications and other condi-
tions was recorded, as was mortality date and cause of
death for those patients who deceased during the study.
Hyperglycemia treatment At each measurement occa-
sion, the practice nurse documented whether patients
were currently treated for their hyperglycemia by diet,
oral agents, insulin or a combination of these treatment
modalities.
Health behaviors/Lifestyle A basic overview of current
and former smoking behavior and alcohol consumption
was collected at the baseline assessment. Changes to
this baseline pattern were recorded during follow-up.
Physical activity was assessed by means of two items.
Patients had to indicate how many hours per week they
spent on (a) “active” (all physical activities other than
practicing sports, e.g. gardening, walking, cycling, climb-
ing stairs) and (b) “sportive” physical activities (e.g.
sports, fitness).
Data acquired using self-report questionnaires
A second questionnaire was completed by the patient at
home and addressed several additional demographic
variables and psychosocial factors. For practical pur-
poses, the questions about health behaviors were trans-
ferred from the interview-administered to the self-report
questionnaire for the follow-up measurements.
Demographics The demographic measures included
marital status (dichotomized as being single versus hav-
ing a partner), living situation (independent versus
dependent of others), employment status (paid employ-
ment versus no paid employment/unemployed/disabled/
retired) and educational level (low education versus
middle/high education).
Depressive symptoms Depressive symptoms during the
last seven days were assessed using a validated Dutch
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This is a 10-item self-rating scale in which each item is
scored on a four-point scale. Total scores range from 0
to 30 points. The EDS was originally developed to mea-
sure post partum depression [39], but has later been
validated in non-postnatal women [40], women around
menopausal age [41], men [42] and community samples
[43]. Although cut-off points for predicting a diagnosis
of clinical depression vary [44], a cut-off score of 12 or
more seems to have satisfactory sensitivity and specifi-
city [41,43].
Type D personality Type D personality was assessed
using the Type D Scale-14 [28]. This questionnaire con-
sists of 14 items, which are scored on a five-point rating
3,017 type 2 diabetes patients 
considered for study inclusion 
Non-response: 
 
Patient: 
- Refused to participate (n = 51) 
- Language difficulties (n = 10) 
- Advanced age (n = 12) 
- Poor physical / mental condition (n = 81) 
- No show for baseline interview (n = 39) 
- Other reasons (n = 89) 
 
Primary care practice nurse: 
- Lack of time (n = 138) 
- Omitting to include a newly diagnosed patient (n = 95) 
- Omitting to include an insulin-using patient (n = 42) 
 
M0: 2,460 patients included 
2,448 patients underwent M0 interview 
1,850 patients returned M0 self-report questionnaire 
Loss to follow-up M1: 
- Deceased (n = 66) 
- Moved (n = 36) 
- Poor physical / mental condition (n = 23) 
- Referral to secondary care (n = 37) 
- Remission of diabetes (n = 8) 
- Main health care provider is general practitioner (n = 4) 
- Refused to participate (n = 7) 
- Forms not returned by primary care practice nurse (n = 19) 
- Other reasons (n = 24) 
- Reason unknown (n = 11) 
M1: 2,225 patients included  2,215 patients underwent M1 interview 
1,642 patients returned M1 self-report questionnaire 
M2: 2,032 patients included 
Loss to follow-up M2: 
- Deceased (n = 51) 
- Moved (n = 18) 
- Poor physical / mental condition (n = 13) 
- Referral to secondary care (n = 30) 
- Remission of diabetes (n = 21) 
- Main health care provider is general practitioner (n = 1) 
- Refused to participate (n = 1) 
- Forms not returned by primary care practice nurse (n = 31) 
- Other reasons (18) 
- Reason unknown (9) 
2,032 patients underwent M2 interview 
1,310 patients returned M2 self-report questionnaire 
Figure 1 Flow chart of the original DIAZOB cohort.
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Variable Categories Measurement occasion
Demographic factors
Age M0
Gender Male, female M0
Ethnicity Dutch, other Caucasian (white Western) groups,
other (Asian, black, Turkish/Moroccan)
M0
Marital status Married/living together, single, LAT relationship, divorced/
separated, widowed
M0,M 1,M 2
Living situation Independent, residing with family/friends, residing in
a nursing home
M0,M 1,M 2
Employment status Paid employment, umemployed, disabled, no paid
employment, retired
M0,M 1,M 2
Education level Primary school, primary vocational education, secondary
school, secondary vocational education, higher vocational
education, university
M0
Medical history
Disease duration Months/years since diabetes diagnosis M0,M 1
Medical history M0: lifetime history:
arterial disease, bypass/angioplasty, myocardial
infarction, stroke, angina pectoris, high cholesterol, kidney
disease, asthma/COPD, cancer,
rheumatic disorder, depression, burn-out
M1 and M2: during last 12 months:
arterial disease, bypass/angioplasty, myocardial
infarction, stroke, angina pectoris, high cholesterol,
asthma/COPD, osteoporosis, depression, kidney disease
M0,M 1,M 2
Treatment
Current hyperglycemia treatment modality None, diet, diet/oral agents, diet/
insulin, diet/oral agents/insulin, other
M0,M 1,M 2
Medication use ACE inhibitors, b-blockers, calcium
antagonists, diuretics, other
antihypertensive agents, statins
M0,M 1,M 2
Laboratory tests
HbA1c M0,M 1,M 2
Fasting glucose M0,M 1,M 2
Cholesterol Total cholesterol M0,M 1,M 2
LDL-cholesterol M0,M 1,M 2
HDL-cholesterol M0,M 1,M 2
Triglycerides M0,M 1,M 2
Protein levels Albumin M0,M 1,M 2
Creatinin M0,M 1,M 2
Albumin-to-creatinin ratio M0,M 1,M 2
MDRD clearance M1,M 2
Physical examination
Length Length in metres M0,M 1,M 2
Weight Weight in kilograms M0,M 1,M 2
Body Mass Index (BMI) Weight in kilograms/(length in metres)
2
Blood pressure Systolic M0,M 1,M 2
Diastolic M0,M 1,M 2
Fundus photography Unassessable, normal, retinopathy M0,M 1,M 2
Foot examination M0: Normal, abnormal
M1 and M2: Normal, neuropathy, ischemia, wound/ulcer,
excessive coldness
M0,M 1,M 2
Lifestyle indicators
Smoking behavior Current smoking: yes/no, number of cigarettes per day M0,M 1,M 2
Additional for M0: smoking history
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comprises two scales, one measuring level of negative
affectivity (NA) and the other social inhibition (SI). Sub-
jects who obtain a score of ten or more on both scales
are considered to have a Type D personality [28]. Both
scales have been shown to be internally consistent
(Cronbach’s a = 0.88 for the NA scale and 0.86 for the
SI scale), stable over an 18-month period [45] and are
independent of mood and health status [28,45].
Other psychosocial factors Social support was mea-
sured using O’Hara’s modified Social Support Scale [46],
comprising three items. Answer categories range from 0
to 4 points, with 0 indicating “no social support at all”
and 4 indicating “extensive social support”. The total
social support score is obtained by adding scores on all
three items. A single item was used to measure feelings
of loneliness in the past 12 months, which were scored
on a scale from 1 to 10 points, with a score of 1 mean-
ing “I never felt lonely” and a score of 10, “I always felt
lonely”. To account for non-diabetes related stressors,
respondents were asked if they had experienced a stress-
ful life event in the previous 12 months (e.g. loss of a
loved one, a break-in, relationship problems, loss of
work, serious financial problems, physical/mental abuse).
Laboratory tests and physical examinations
Biomedical parameters were derived from standard care
laboratory tests and physical examinations carried out
by the Diagnostic Centre Eindhoven, a primary care
institution where biological records of the regional dia-
betes population are filed after each regular care check-
up appointment. For the DIAZOB project, blood was
drawn annually to determine glycemic control (glycosy-
lated hemoglobin or HbA1C levels, fasting glucose), crea-
tinin, the MDRD clearance (only at follow-up) and
cholesterol values (total, LDL, HDL, triglycerides); urine
samples were taken to assess albumin and the albumin-
to-creatinin ratio. As for the physical examination,
blood pressure measurements (systolic and diastolic),
body mass index (BMI; weight in kilograms/length in
metres
2), and fundus photography and foot screening
results were provided. To diagnose retinopathy, digital
fundus photography was carried out by a biometrist and
interpreted by an ophthalmologist. Foot screening
included a neurological and vascular examination (Dop-
pler test), and inspection of feet and shoes by a
podotherapist or a biometrist under supervision. For the
baseline measurement, only the presence of abnormal-
ities to the feet was recorded. During follow-up testing,
the lower extremities were assessed for neuropathy,
ischemia, wounds/ulcers and excessive coldness.
Pharmacy medication records
With the patient’s consent, information regarding pre-
scribed medication was obtained from local pharmacists.
In addition to the medication applied for the manage-
ment of hyperglycemia, the use of cardiovascular agents
(including several antihypertensives and a class of cho-
lesterol-lowering drugs) was registered.
Ethical principles
This study was planned and conducted in accordance
with the medical professional codex and the Helsinki
Declaration of 1996 [47]. Written informed consent was
obtained from all participants. The study protocol of the
DiaDDZoB Study was approved by the medical research
ethics committee of a local hospital, the Máxima Medi-
cal Centre in Veldhoven (NL27239.015.09).
Planned statistic analyses
Statistical analyses will be performed using the latest
version of the Statistical Package for Social Sciences
(SPSS). A p < 0.05 significance level will be adopted in
all statistical tests. As the number of previous studies on
these research topics is limited, we choose to use two-
sided tests in all analyses.
Frequencies will be provided for (1) the prevalence,
(2) incidence (with/without self-reported history of
Table 1: Measurements included in the DiaDDZoB Study (Continued)
Alcohol consumption Current alcohol consumption: yes/no, number of
consumptions per week
M0,M 1,M 2
Additional for M0: history of alcohol consumption
Physical activity Hours per week of active physical activity M0,M 1,M 2
Hours per week of sportive physical activity M0,M 1,M 2
Psychological factors
Depressive symptoms Edinburgh Depression Scale (EDS) M0,M 1,M 2
Type D personality Type D Scale-14 (DS14) M1,M 2
Social support O’Hara’s modified Social Support Scale M0,M 1,M 2
Loneliness Single item concerning feelings of loneliness in
the past 12 months
M0,M 1,M 2
Stressful life events Single item concerning stressful life event(s) in
the past 12 months
M0,M 1,M 2
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Page 7 of 11depression), (3) recurrence (high score across two or
three assessments) and (4) other patterns of relapse and
remission of high depressive symptoms (EDS-score of
12 or more). In addition, logistic regression analyses will
be used to determine significant predictors of these dif-
ferent course patterns. Baseline characteristics of
patients with/without high depressive symptoms (EDS-
score of 12 or more) and with/without a Type D per-
sonality will be compared using independent-samples
t-tests and X
2 tests. To evaluate the vascular risk asso-
ciated with increased levels of emotional distress, we
will perform logistic regression analyses for (1) the
development of each separate micro- and macrovascular
complication and (2) a composite measure of vascular
disease (the development of any vascular condition) dur-
ing the two year follow-up period, with either depres-
sion or Type D personality as the independent variable.
The group of participants with low depressive symptoms
or no Type D personality, respectively, will be used as
the reference category. Analogous analyses will be used
for mortality, with the dependent variable defined as (1)
all-cause mortality or (2) (cardio)vascular mortality, as
registered in primary care medical records up until
December 2008. Before proceeding to the multivariate
statistics, several study variables will be evaluated for
their potential as confounders or mediators in the asso-
ciation between emotional distress and disease outcomes
(the onset/progression of micro- and macrovascular
complications, all-cause and vascular mortality). In line
with the methods used in a study by Whooley et al.
[33], we will adopt a > 5% change in the effect size
(odds ratio) for emotional distress before and after
adjustment for the variable in question as the criterion
to identify suitable mediating or confounding factors.
All variables satisfying these conditions will be included
in the final logistic regression models. In addition, we
will look at mediating variables more closely using one
of the statistical methods described in the recent article
by MacKinnon, Fairchild and Fritz [48].
Power calculation
The sample size was determined using PASS 2008 [49]
and was based on the logistic regression analyses for the
main research question (“Do patients with type 2 dia-
betes and co-morbid emotional distress have an
increased risk for the onset/progression of micro- and
macrovascular complications?”). Assuming a power of
0.80, an alpha level of 0.05, two-sided testing, and a
baseline prevalence rate of 20% for the binary indepen-
dent variable (either high levels of depressive symptoms
or Type D personality), we calculated the sample size
for a range of scenarios. Based on earlier primary care
and community studies [19,27] and on known character-
istics of the DIAZOB population, we expect a two-year
cumulative event rate (the development of any vascular
complication) of 10 - 15%. In psychological research, R
2
(achieved when emotional distress is regressed on the
other independent variables) usually ranges from 0.20 -
0.30. Assuming equivalence between OR/RR/HR due to
the relatively low event rate of vascular outcomes, the
majority of earlier studies on the risk of vascular disease
in diabetes patients, primary care/community samples
and post-myocardial infarction patients has found an
effect size for depression of approximately 1.5 - 2.0
[23,24,27]. Therefore, the entered values were either
0.10, 0.125 or 0.15 for P0 (the probability that a partici-
pant develops any vascular complication during the two
year follow-up period, given that he/she has a low level
of depressive symptoms or no Type D personality at
baseline), 0.20, 0.25 or 0.30 for R
2, and 1.5, 1.75 or 2.0
for the OR. Sample sizes ranged from 3905 in the most
conservative scenario (P0 =1 0 ,R
2 =0 . 3 0a n dO R=1 . 5 )
to 764 in the least restricted scenario (P0 =1 5 ,R
2 =
0.20 and OR = 2.0). When positing a middle-ground
scenario (P0 =0 . 1 2 5 ;R
2 = 0.25 and OR = 1.75), the
study needs a total of 1499 participants to detect an OR
of 1.75. Anticipating an annual 10% loss to follow-up
(death, serious illness, moving), we need to include
approximately 1850 patients at baseline. As we expect a
40% non-response/exclusion rate, we will consider for
eligibility the total patient group (n ≈ 3000).
Discussion
As the prevalence of type 2 diabetes is high and the
absolute numbers of patients with both diabetes and
depression will continue to rise considerably in the next
decades, it has become even more essential to further
increase our understanding of the associations between
diabetes and depression. Currently, our knowledge
about this area is still limited. The present paper gives
an outline of the theoretical background and methodol-
ogy of the DiaDDZoB Study, a Dutch prospective cohort
study in primary diabetes care, which aims to answer
several key research questions regarding the course and
vascular impact of depression and Type D personality in
patients with type 2 diabetes.
The major strengths of the DiaDDZoB Study include
its longitudinal design and relatively large sample size,
its focus on type 2 diabetes patients who are being trea-
ted in a primary care setting, the wealth of detailed
patient information that is available, and the policy to
verify self-reported disease by inspection of medical
records. The results of this study may lead to the identi-
fication of high risk patients and could guide the devel-
opment of future intervention studies.
While the DIAZOB Primary Care Diabetes study aims
to include a relatively unselected patient population,
depressive symptoms (including a depressed mood or
Nefs et al. BMC Public Health 2010, 10:388
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diminished ability to think or concentrate) could have
negatively affected the initial decision to participate in
those patients who would otherwise have screened posi-
tive for depression on the EDS. In a similar vein, as the
nurse-led interview required a certain amount of open-
ness and direct communication with a health provider
about disease and concurrent complaints, social inhibi-
tion might have deterred patients with a Type D person-
ality. In a study of 178 patients with chronic heart
failure, patients with a Type D personality not only
experienced and worried more about cardiac symptoms,
they also were less likely to report these symptoms to
their cardiologist or nurse [50].
The sharp rise in the number of patients with type 2
diabetes has resulted in a gradual shift from secondary
to primary care, thereby placing considerable demands
on primary health care teams [51]. Secondary care
consultations or referrals are indicated in case of more
complex disease management, e.g. in the presence of
complications or poorly regulated blood glucose levels
[52,53]. Seeing that approximately 3% (67/2,460) of all
patients participating in the baseline assessment
dropped out of the study after a secondary care refer-
ral, future assessments should be planned and carried
out in close cooperation with hospital practitioners to
keep the cohort intact. To alleviate some of the work-
load for general practitioners, the primary care nurse
specialist has been introduced as the main care-provi-
der for patients with type 2 diabetes in family practice
[54]. Since nurse practitioners generally provide longer
consultations and are trained to focus on the medical,
practical as well as the emotional aspects of diabetes
[55], depression prevalence estimates could have been
lowered with more adequate detection and subsequent
treatment of depression. Unfortunately, earlier work
has shown that the reverse is probably true, i.e. the
presence of emotional problems was recorded in the
medical chart in only 20 - 30% of diabetes patients
with high scores on questionnaires measuring emo-
tional distress [55].
Although a recent cohort study has investigated
whether depression runs a chronic course with high
rates of recurrence in primary care [12], there is a pau-
city of research on the trajectory of emotional distress
in specific chronic diseases. While our annual screening
method most likely will identify a subsample with recur-
rent, high levels of depressive symptoms, a prospective
design with yearly follow-up assessments will by defini-
tion miss some patients with a relapsing-remitting
symptom profile who happen to be in complete or par-
tial remission at the assessment occasion. While an in-
depth characterization of short-term fluctuations in
emotional distress goes beyond the initial goals of the
DIAZOB project, a similar model offers interesting
research perspectives for future studies.
A structured psychiatric interview using DSM-IV cri-
teria is considered the gold standard for diagnosing clin-
ical depression [56]. While self-report questionnaires
were originally developed to quantify the severity of
depression, they are often adopted as time-efficient
case-finding instruments in large samples [57]. However,
depression is not the only common emotional problem
in diabetes patients [58,59]. Depression questionnaires
may detect some [56], but certainly not all [58] compo-
nents of distress. Given the tendency of psychosocial
factors to cluster together within individuals [60,61], the
simultaneous assessment of multiple distress types
seems justified to obtain a more precise risk stratifica-
tion [60]. Other studies have emphasized the importance
of examining both episodic emotional states and more
chronic psychosocial factors [60,62]. By extending the
focus of our research from a cross-sectional assessment
of depressive symptoms to repeated measurements of
not only depression, but also Type D personality, we
intend to take a step in this direction.
Several other study limitations need to be mentioned.
First, while laboratory determinations and physical
examinations are part of regular care protocols and
therefore did not impose an extra burden on the partici-
pating patients, we cannot avoid that for some patients
these tests were scheduled several months before or
after the official measurement occasion in question. In
these cases, we used the test results that were the clo-
sest in time to the rest of the data. Secondly, although
the prescription of antihyperglycemic and cardiovascular
agents was documented relatively well, information on
the concurrent use of psychotropic medication is lack-
ing. Earlier studies have suggested that different classes
of antidepressant drugs may exert a clinically relevant
positive or negative effect on glucose-insulin homeosta-
sis [63]. Requesting pharmacy information from large
databases of pharmacy dispensing records [64] might
improve the accuracy of medication registration. Finally,
although we aim to elucidate the mechanisms responsi-
ble for the adverse effect of emotional distress on vascu-
lar outcomes, no information was available on several
interesting candidate mechanisms, including dysfunc-
tional activity of the hypothalamic-pituitary-adrenal axis,
neurotransmitter function or inflammatory processes
[31-33].
General practice settings offer relatively favorable con-
ditions for conducting longitudinal research, as the
Dutch health care system is characterized by a high
level of care continuity between patients and family phy-
sicians [65]. In enhancing the quality of longitudinal
data collection, it is essential to ensure the provision of
solid research facilities, standardization of data between
Nefs et al. BMC Public Health 2010, 10:388
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patient care data collection in a clinician-friendly man-
ner [65]. Planning and conducting longer term epide-
miologic studies considerably challenges the motivation
and benevolence of participating health care providers.
Apart from central coordination of the DIAZOB
research infrastructure, PoZoB also contributes to a clin-
ical translation of scientific findings by organising feed-
back meetings and training programmes, thus enabling
an ongoing research commitment of general practi-
tioners and their staff [65]. Keeping an eye on the needs
and developments in primary care daily practice, the
collaboration between PoZoB and CoRPS, Tilburg Uni-
versity, will provide an excellent framework to explore
the wealth of information already available and at the
same time ensure a continuing qualitative and innova-
tive development of primary care diabetes research.
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